Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry.
Haemophilia is a rare disease. To improve knowledge, prospective studies of large numbers of subjects are needed. To establish a large well-documented birth cohort of patients with haemophilia enabling studies on early presentation, side effects and outcome of treatment. Twenty-one haemophilia treatment centres have been collecting data on all children with haemophilia with FVIII/IX levels up to 25% born from 2000 onwards. Another eight centres collected data on severe haemophilia A only. At baseline, details on delivery and diagnosis, gene mutation, family history of haemophilia and inhibitors are collected. For the first 75 exposure days, date, reason, dose and product are recorded for each infusion. Clinically relevant inhibitors are defined as follows: at least two positive inhibitor titres and a FVIII/IX recovery <66% of expected. For inhibitor patients, results of all inhibitor- and recovery tests are collected. For continued treatment, data on bleeding, surgery, prophylaxis and clotting factor consumption are collected annually. Data are downloaded for analysis annually. In May 2013, a total of 1094 patients were included: 701 with severe, 146 with moderate and 247 with mild haemophilia. Gene defect data were available for 87.6% of patients with severe haemophilia A. The first analysis, performed in May 2011, lead to two landmark publications. The outcome of this large collaborative research confirms its value for the improvement of haemophilia care. High-quality prospective observational cohorts form an ideal source to study natural history and treatment in rare diseases such as haemophilia.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands.
K
K
Fischer
R
R
Ljung
H
H
Platokouki
R
R
Liesner
S
S
Claeyssens
E
E
Smink
H M
HM
van den Berg
D002648:Child; D002675:Child, Preschool; D005060:Europe / Q000453:epidemiology; D005164:Factor IX / Q000276:immunology / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D006470:Hemorrhage / Q000150:complications; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007518:Isoantibodies / Q000276:immunology; D010641:Phenotype; D011446:Prospective Studies; D035583:Rare Diseases / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D012042:Registries
D007518:Isoantibodies; D005169:Factor VIII; D005164:Factor IX
cohort study; inhibitors; outcome; phenotype; prophylaxis; study design